Intelligent Bio Solutions Launches Study to Achieve Sub-3-Minute Drug Screening
Intelligent Bio Solutions launched a validation study for its fingerprinting cartridge to reduce analysis time from ten to under three minutes, targeting a two-minute goal. The U.S. roadside drug testing market, valued at $1.17 billion and projected to $1.62 billion by 2030, expands INBS’s market as it pursues FDA 510(k) clearance.
1. Validation Study to Accelerate Test Times
Intelligent Bio Solutions has initiated a preliminary validation study aimed at cutting its Intelligent Fingerprinting Drug Screening System’s analysis time from ten minutes to under three minutes, with a two-minute test goal. The system currently collects samples in under a minute and delivers results at the point of collection, and this study will confirm earlier findings and refine performance.
2. Expanding Roadside Testing Market
The U.S. roadside drug testing market was valued at $1.17 billion in 2023 and is projected to reach $1.62 billion by 2030 at a 4.71% CAGR. Faster analysis could transform roadside enforcement by increasing testing throughput, mirroring the impact of breathalyzers, and opens opportunities in additional verticals such as drug treatment, rehabilitation, and consumer health.
3. Regulatory Pathway and Future Applications
INBS’s system is currently deployed in the Forensic Use Only market in the U.S. and the company is pursuing FDA 510(k) clearance for opiate detection to enable broader commercial use. Achieving sub-three-minute results would provide a competitive advantage as states expand drug testing programs and could accelerate entry into multiple high-value segments beyond workplace testing.